alexa Characterization of a novel impurity in bulk drug eprosartan by ESI MS(n) and NMR.
Pharmaceutical Sciences

Pharmaceutical Sciences

Pharmaceutica Analytica Acta

Author(s): Sun C, Wu J, Wang D, Pan Y

Abstract Share this page

Abstract A simple and sensitive liquid chromatography tandem multi-stage mass spectrometry (HPLC/MS(n)) method suitable for eprosartan analysis was developed, by which an unknown impurity in bulk drug eprosartan was detected. The fragmentation behavior of eprosartan and the impurity in negative mode was investigated. Two molecules of CO2 lost from eprosartan precursor ion were observed, while four molecules of CO2 were extruded from the deprotonated molecular ion to the MS(3) product ions of the impurity. Furthermore, a characteristic fragmentation ion at m/z 335 was observed in both eprosartan and the impurity indicated that the impurity might have two eprosartan units. The unknown impurity was initially proposed to be eprosartan dimer connected via methylene unit at the thiophene moiety on the basis of the multi-stage mass spectrometric and exact mass evidences, and it was finally elucidated as 4,4'-(5,5'-(1E,1'E)-3,3'-(4,4'-methylenebis(thiophene-4,2-diyl))bis(2-carboxyprop-1-ene-3,1-diyl)bis(2-butyl-1H-imidazole-5,1-diyl))bis(methylene) dibenzoic acid by NMR experiments including 1D ((1)H NMR, (13)C NMR, DEPT135(0)) and 2D ((1)H-(1)HCOSY, HMQC and HMBC) data. This article was published in J Pharm Biomed Anal and referenced in Pharmaceutica Analytica Acta

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords